Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to the ongoing pandemic. This document is the public summary of the market shaping roadmap for COVID-19 vaccines.

In 2021, Gavi helped launch the Ebola vaccine emergency stockpile of licensed vaccines to respond to outbreaks of Ebola virus disease. Subsequently in 2024, Gavi opened a funding window for preventive vaccination among high-risk groups, on the back of WHO’s updated recommendations. This document is the public summary of the market shaping roadmap for Ebola vaccines.

Human papillomavirus (HPV) is the primary cause of cervical cancer. The roadmap is a foundational tool of Gavi’s market shaping strategy, with the purpose of articulating a long-term vision and market strategy designed to align market shaping objectives and target outcomes across the Alliance partners; define a set of interventions to reach these objectives and target outcomes; and inform procurement strategies and decisions.

At its November 2013 Board meeting, the Vaccine Alliance opened a funding window for Japanese encephalitis (JE) catch-up campaigns in endemic countries. Download the public summary of the supply and procurement roadmap to learn more about Gavi’s market shaping objectives for the JE vaccine market.

Gavi Board approved a funding window for malaria vaccines in December 2021 to support the use of malaria vaccines in routine immunisation programmes. This document is the public summary of the market shaping roadmap for malaria vaccines.

Gavi’s engagement on measles dates to 2004 and rubella support began in 2011 through the measles-rubella (MR) vaccine. By the end of 2016, Gavi had supported 50 countries with MR programmes. This public summary of the supply and procurement roadmap describes the market, and outlines Gavi’s market shaping ambitions for MR vaccines.

Gavi supports meningococcal vaccines for use in campaigns and routine immunisation in endemic countries in Africa. This document is the public summary of the supply and procurement roadmap for meningococcal vaccine.

In 2008, the Gavi Board approved the strategy to eliminate serogroup A meningococcal meningitis and in 2016, the Gavi Board approved the emergency stockpile commitment to be extended indefinitely. This document is the public summary of the supply and procurement roadmap for meningococcal vaccines for outbreak response.

Gavi has been engaged in cholera vaccination since 2014 through the funding and support of the global stockpile of cholera vaccines. This document is the public summary of the  market shaping roadmap for oral cholera vaccines.

In 2013, the Gavi Board decided to fund the introduction of inactivated polio vaccine (IPV) in all Gavi-supported countries, and in 2018, it approved support for DTwP-containing boosters and in-principle support for Hexavalent which combines Pentavalent (DTwP-HepB-Hib) and IPV antigens. This document is the public summary of the supply and procurement roadmap for these four interrelated markets.

Gavi has supported routine introductions with pneumococcal vaccine since 2009. Find out more about the pneumococcal vaccine market, and Gavi’s approach to shaping it, in the public summary of the vaccine roadmap.

Rotavirus is the leading cause of severe diarrhoea in children under five years of age worldwide. This document is the public summary of the supply and procurement roadmap for rotavirus vaccine.

Gavi opened a funding window for typhoid conjugate vaccine in November 2017, supporting catch-up campaigns and co-financing of the vaccine use in routine immunisation programmes. This document is the public summary of the supply and procurement roadmap for TCV.

In November 2018, the Gavi Board approved allocation of USD 13.5 million as funding to support a three-year multi-faceted programme to improve yellow fever laboratory capacity in Africa during 2019-2021. This document is the public summary of the supply and procurement roadmap for yellow fever laboratory diagnostics for routine and outbreak yellow fever testing.

Gavi has been engaged in yellow fever (YF) vaccination since 2001 in support of WHO efforts to control the disease. This document is the public summary of the supply and procurement roadmap for yellow fever vaccine.

Gavi established the Cold Chain Equipment Optimisation Platform (CCEOP) in June 2015 as a strategic and targeted approach to address the challenges of improving the vaccine cold chain with higher-performing equipment and meeting unmet country needs. This document provides a public summary of the market shaping roadmap for two CCE product categories: Ice-lined (ILR) & Solar Direct Drive (SDD) refrigerators/ freezers.

Cholera diagnostic tests are useful for targeting cholera prevention and control measures, including use of oral cholera vaccines (OCV).The Gavi Alliance is working to make fit-for-purpose cholera diagnostic tests available to countries eligible for Gavi new vaccine support in order to make cholera vaccination efforts more effective, efficient, and equitable. This document is the public summary of the market shaping supply and procurement roadmap for cholera diagnostic tests.

Gavi, the Vaccine Alliance is working to make fit-for-purpose measles rapid diagnostic tests available to countries eligible for Gavi support for measles-containing vaccines. These are intended to guide decision-making for immunisation programmes and targeting of measles prevention and control measures. This document is a public summary of the market shaping supply and procurement roadmap for measles diagnostic tests.

The roadmap is a foundational tool of Gavi’s market shaping strategy. Its purpose is to articulate a mid- and long-term market strategy designed to align market shaping objectives and target outcomes across the Vaccine Alliance partners; define a set of interventions to reach these objectives and target outcomes; and inform procurement strategies and decisions.